JP2001520521A - Ｖｐ２２タンパク質及びその使用 - Google Patents

Ｖｐ２２タンパク質及びその使用

Info

Publication number
JP2001520521A
JP2001520521A JP54522798A JP54522798A JP2001520521A JP 2001520521 A JP2001520521 A JP 2001520521A JP 54522798 A JP54522798 A JP 54522798A JP 54522798 A JP54522798 A JP 54522798A JP 2001520521 A JP2001520521 A JP 2001520521A
Authority
JP
Japan
Prior art keywords
protein
cells
cell
microtubules
microtubule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP54522798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001520521A5 (enExample
Inventor
ダフネ エリオット，ジリアン
Original Assignee
フォゲン リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォゲン リミティド filed Critical フォゲン リミティド
Publication of JP2001520521A publication Critical patent/JP2001520521A/ja
Publication of JP2001520521A5 publication Critical patent/JP2001520521A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP54522798A 1997-03-21 1998-03-23 Ｖｐ２２タンパク質及びその使用 Ceased JP2001520521A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9705903.4A GB9705903D0 (en) 1997-03-21 1997-03-21 VP22 Proteins and uses thereof
GB9705903.4 1997-03-21
PCT/GB1998/000873 WO1998042742A1 (en) 1997-03-21 1998-03-23 Vp22 proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2001520521A true JP2001520521A (ja) 2001-10-30
JP2001520521A5 JP2001520521A5 (enExample) 2005-11-10

Family

ID=10809645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54522798A Ceased JP2001520521A (ja) 1997-03-21 1998-03-23 Ｖｐ２２タンパク質及びその使用

Country Status (7)

Country Link
US (2) US20020128174A1 (enExample)
EP (1) EP0971953A1 (enExample)
JP (1) JP2001520521A (enExample)
AU (1) AU6739398A (enExample)
CA (1) CA2283794A1 (enExample)
GB (1) GB9705903D0 (enExample)
WO (1) WO1998042742A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
GB9816761D0 (en) 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
WO2000053722A2 (en) * 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US6451601B1 (en) 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
GB9930519D0 (en) 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
US6688084B2 (en) * 2000-03-24 2004-02-10 International Paper Company Automated bulk box strapper
ATE512674T1 (de) * 2003-01-06 2011-07-15 Angiochem Inc Angiopep-1, verwandte verbindungen, und deren verwnedungen
US9365634B2 (en) * 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN102026667B (zh) 2008-04-18 2014-06-25 安吉奥开米公司 紫杉醇、紫杉醇类似物或紫杉醇结合物的药物组合物及相关制备方法和用途
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US8828925B2 (en) 2008-10-15 2014-09-09 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
WO2010063122A1 (en) 2008-12-05 2010-06-10 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
RU2011146654A (ru) 2009-04-20 2013-05-27 Ангиокем Инк. Способы лечения рака яичников с применением конъюгированного средства
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5059699A (en) 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
TW223634B (enExample) 1991-03-18 1994-05-11 Kingston David G I
FR2679230B1 (fr) 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
WO1993014787A1 (en) 1992-01-31 1993-08-05 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5356927A (en) 1992-12-02 1994-10-18 Thomas Jefferson University Methods of treating plasmodium and babesia parasitic infections
AU5735094A (en) 1992-12-02 1994-06-22 Thomas Jefferson University Methods of killing protozoal parasites
US5583153A (en) * 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
AU705563B2 (en) * 1995-07-28 1999-05-27 Marie Curie Cancer Care Transport proteins and their uses
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses

Also Published As

Publication number Publication date
US20050118717A1 (en) 2005-06-02
AU6739398A (en) 1998-10-20
US7067632B2 (en) 2006-06-27
EP0971953A1 (en) 2000-01-19
GB9705903D0 (en) 1997-05-07
US20020128174A1 (en) 2002-09-12
WO1998042742A1 (en) 1998-10-01
CA2283794A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
US8551951B2 (en) Pharmaceutical preparations and methods for inhibiting tumors
US7067632B2 (en) VP22 proteins and uses thereof
JP2019512458A (ja) Ｒｎａによって誘導された、ヒトｊｃウイルス及び他のポリオーマウイルスの根絶
US20050202075A1 (en) Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
CA2600370A1 (en) Bioactive fus1 peptides and nanoparticle-polypeptide complexes
AU7750191A (en) Gene therapy for cell proliferative diseases
PT2040728E (pt) Fkbp-l e seus usos como inibidores de angiogénese
US20090011984A1 (en) Biotin-binding receptor molecules
Klotzsche et al. Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (vimentin) scaffold
AU2002213691A1 (en) Pharmaceutical preparations and methods for inhibiting tumors
WO1997025056A1 (en) High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor
CA2395575A1 (en) Uses of transport proteins for controlling cell cycle
JP2000510112A (ja) ＴＧＦ―β拮抗物質としてのプロラクチンの使用方法
US6217864B1 (en) Method for targeted degradation of intracellular proteins in vivo or ex vivo
WO2004000236A2 (en) Modified sodium iodide symporter proteins and genes for imaging and cancer therapy
JP4733394B2 (ja) 大腸癌転移抑制剤
US20030144236A1 (en) Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1)
WO1999055380A1 (en) Nr-CAM GENE, NUCLEIC ACIDS AND NUCLEIC ACID PRODUCTS FOR THERAPEUTIC AND DIAGNOSTIC USES FOR TUMORS
AU783081B2 (en) VP22 proteins and uses thereof
CA2359650C (en) Pharmaceutical preparations and methods for inhibiting tumors
US7176179B1 (en) Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide
MXPA99008620A (en) Vp22 proteins and uses thereof
AU770157B2 (en) Use of semaphorin for modulation of cellular efflux
AU2003283277A1 (en) Delocalization molecules and use thereof
AU2007249137A1 (en) Pharmaceutical preparations and methods for inhibiting tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071204

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080617